4722 related articles for article (PubMed ID: 6143562)
21. Mechanisms of resistance to 6-aminonicotinamide.
Saunders PP; Muhs MA; Arimilli S
Anticancer Res; 1996; 16(2):843-8. PubMed ID: 8687139
[TBL] [Abstract][Full Text] [Related]
22. Furanfurin and thiophenfurin: two novel tiazofurin analogues. Synthesis, structure, antitumor activity, and interactions with inosine monophosphate dehydrogenase.
Franchetti P; Cappellacci L; Grifantini M; Barzi A; Nocentini G; Yang H; O'Connor A; Jayaram HN; Carrell C; Goldstein BM
J Med Chem; 1995 Sep; 38(19):3829-37. PubMed ID: 7562914
[TBL] [Abstract][Full Text] [Related]
23. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193)--II. Relationship between dose level and biochemical effects in P388 leukemia in vivo.
Jayaram HN; Smith AL; Glazer RI; Johns DG; Cooney DA
Biochem Pharmacol; 1982 Dec; 31(23):3839-45. PubMed ID: 6130768
[TBL] [Abstract][Full Text] [Related]
24. IMP dehydrogenase: inhibition by the anti-leukemic drug, tiazofurin.
Yamada Y; Natsumeda Y; Yamaji Y; Jayaram HN; Tricot GJ; Hoffman R; Weber G
Leuk Res; 1989; 13(2):179-84. PubMed ID: 2564451
[TBL] [Abstract][Full Text] [Related]
25. Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase.
Yamada Y; Natsumeda Y; Weber G
Biochemistry; 1988 Mar; 27(6):2193-6. PubMed ID: 2897864
[TBL] [Abstract][Full Text] [Related]
26. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM
Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813
[TBL] [Abstract][Full Text] [Related]
27. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
Weber G; Nagai M; Natsumeda Y; Eble JN; Jayaram HN; Paulik E; Zhen WN; Hoffman R; Tricot G
Cancer Commun; 1991 Mar; 3(3):61-6. PubMed ID: 1705812
[TBL] [Abstract][Full Text] [Related]
28. Unique bioactivation of tiazofurin--studies with resistant cells.
Kuttan R
Indian J Biochem Biophys; 1989 Jun; 26(3):160-5. PubMed ID: 2620910
[TBL] [Abstract][Full Text] [Related]
29. IMP dehydrogenase and action of antimetabolites in human cultured blast cells.
Yamada Y; Goto H; Yoshino M; Ogasawara N
Biochim Biophys Acta; 1990 Mar; 1051(3):209-14. PubMed ID: 1968764
[TBL] [Abstract][Full Text] [Related]
30. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
[TBL] [Abstract][Full Text] [Related]
31. Tiazofurin: molecular and clinical action.
Weber G; Prajda N; Abonyi M; Look KY; Tricot G
Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxicity of tiazofurin and its arabinose and xylose analogues in K562 cells.
Zhen W; Jayaram HN; Marquez VE; Goldstein BM; Cooney DA; Weber G
Biochem Biophys Res Commun; 1991 Oct; 180(2):933-8. PubMed ID: 1683233
[TBL] [Abstract][Full Text] [Related]
33. Tiazofurin action in leukemia: evidence for down-regulation of oncogenes and synergism with retinoic acid.
Weber G; Yamaji Y; Nagai M; Natsumeda Y; Jayaram HN; Zhen WN; Paulik E
Adv Enzyme Regul; 1990; 30():35-45. PubMed ID: 2206022
[TBL] [Abstract][Full Text] [Related]
34. Ribavirin, tiazofurin, and selenazofurin: mononucleotides and nicotinamide adenine dinucleotide analogues. Synthesis, structure, and interactions with IMP dehydrogenase.
Gebeyehu G; Marquez VE; Van Cott A; Cooney DA; Kelley JA; Jayaram HN; Ahluwalia GS; Dion RL; Wilson YA; Johns DG
J Med Chem; 1985 Jan; 28(1):99-105. PubMed ID: 2856943
[TBL] [Abstract][Full Text] [Related]
35. Purine metabolism of human glioblastoma in vivo.
Pillwein K; Chiba P; Knoflach A; Czermak B; Schuchter K; Gersdorf E; Ausserer B; Murr C; Goebl R; Stockhammer G
Cancer Res; 1990 Mar; 50(5):1576-9. PubMed ID: 2154328
[TBL] [Abstract][Full Text] [Related]
36. Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide).
Boritzki TJ; Berry DA; Besserer JA; Cook PD; Fry DW; Leopold WR; Jackson RC
Biochem Pharmacol; 1985 Apr; 34(7):1109-14. PubMed ID: 3985993
[TBL] [Abstract][Full Text] [Related]
37. Control of enzymic programs and nucleotide pattern in cancer cells by acivicin and tiazofurin.
Weber G; Natsumeda Y; Lui MS; Faderan MA; Liepnieks JJ; Elliott WL
Adv Enzyme Regul; 1984; 22():69-93. PubMed ID: 6206692
[TBL] [Abstract][Full Text] [Related]
38. Tiazofurin: biological effects and clinical uses.
Tricot G; Jayaram HN; Weber G; Hoffman R
Int J Cell Cloning; 1990 May; 8(3):161-70. PubMed ID: 2189014
[TBL] [Abstract][Full Text] [Related]
39. Action of 2-beta-D-ribofuranosylthiazole-4-carboxamide (tiazofurin) against untreated human ovarian cancers in the murine xenograft assay.
Micha JP; Kucera PR; Preve CU; Rettenmaier MA; Stratton JA; DiSaia PJ
Gynecol Oncol; 1985 Jul; 21(3):351-5. PubMed ID: 4007612
[TBL] [Abstract][Full Text] [Related]
40. Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells.
Olah E; Natsumeda Y; Ikegami T; Kote Z; Horanyi M; Szelenyi J; Paulik E; Kremmer T; Hollan SR; Sugar J
Proc Natl Acad Sci U S A; 1988 Sep; 85(17):6533-7. PubMed ID: 2901100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
